Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
The company is a privately held pharmaceutical company focused on pharmaceutical product development in the drug development process.
Orbicular Pharmaceutical Technologies Private Limited, is an unlisted private company incorporated on 13 August, 2008. It is classified as a private limited company and is located in Hyderabad, Telangana. It's authorized share capital is INR 12.00 cr and the total paid-up capital is INR 11.18 cr.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
13.68%
46.69%
-42.36%
20.3%
14.77%
17.42%
-3.23
12.99
-10.33
-28.38
5.23
-0.01
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(3)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Kotak Mahindra Bank Limited
No. of Loans: 5
Total Amount : 124.2 cr
ICICI Bank Limited
No. of Loans: 6
Total Amount : 68.8 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Meena Mohan
Shareholder
|
02121102 | 16 years |
| Managing Director | Sivaraman Mohan Mailatur
Shareholder
|
02573448 | 14 years |
| Director | Hiren Dasharathbhai Patel
Shareholder
|
03560495 | 12 years |
| Director | Visalakshi Chandramouli | 03594109 | 1 years |
| Director | Rahul Gawande Sudhakar
Shareholder
|
07477010 | 5 years |
| Director | Bhaveshkumar Vallabhbhai Patel
Shareholder
|
07932528 | 3 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| REVITOS SPECIALITIES PRIVATE LIMITED |
Active
|
50.0 L | 2 | Telangana |
| GENEROUS GIVING FOUNDATION |
Active
|
1.0 L | 2 | Telangana |
| INVITRON ADVANCED ANALYTICS PRIVATE LIMITED |
Active
|
57.3 L | 5 | Telangana |
| MEDGENE PHARMACEUTICALS PRIVATE LIMITED |
Amalgamated
|
10.0 L | 1 | Karnataka |
| ORUS LIFE SCIENCES PRIVATE LIMITED |
Active
|
1.0 L | 2 | Telangana |
| DEEPTEK MEDICAL SERVICES PRIVATE LIMITED |
Active
|
2.1 L | 1 | Maharashtra |
| BRINTON HEALTHCARE LIMITED |
Active
|
1.0 L | 1 | Maharashtra |
| LINUX LABORATORIES PRIVATE LIMITED |
Active
|
1.2 Cr | 1 | Tamil Nadu |
| ANDERSON DIAGNOSTIC SERVICES PRIVATE LIMITED |
Active
|
1.1 Cr | 1 | Tamil Nadu |
| SAKAR HEALTHCARE LIMITED |
Active
|
21.7 Cr | 1 | Gujarat |
| DEEPTEK MEDICAL IMAGING PRIVATE LIMITED |
Active
|
19,930.0 | 1 | Maharashtra |
| BRINTON PHARMACEUTICALS LIMITED |
Active
|
1.1 Cr | 1 | Maharashtra |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| INVITRON ADVANCED ANALYTICS PRIVATE LIMITED | Telangana | 2013 | ₹ 57.3 L |
The incorporation date of ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED is 13 August, 2008
The authorized share capital of ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED is INR ₹ 12.0 Cr.
The paid-up capital of ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED is INR ₹ 11.2 Cr.
The registered address of ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED is P.No 53 , ALEAP Industrial Estate, Gajularamaram Behind Pr agathi Nagar, Kukatpally NA HYDERABAD Hyderabad Telangana - 500090
The CIN number of ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED is U24233TG2008PTC060606.
Expand
Delete
Collapse
See
details
